Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 9/20 | 0.45 |
| ▸ | EGFR | P00533 | 5/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.37 |
| ▸ | CDK9 | P50750 | 4/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17822328 | 0.86 | EGFR (0.47) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL30883808 | 0.86 | EGFR (0.47) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL30883810 | 0.86 | EGFR (0.47) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL18607276 | 0.85 | EGFR (0.52) | EGFR | |
| SCHEMBL18607148 | 0.80 | MKNK2 (0.46) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL19114738 | 0.77 | EGFR (0.57) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL17384791 | 0.77 | EGFR (0.56) | MKNK2EGFRCCNT1CDK9MKNK1 | |
| SCHEMBL14660649 | 0.77 | EIF2AK2 (0.57) | MKNK2EGFRMKNK1FLT3CDK4 | |
| SCHEMBL17059241 | 0.76 | EGFR (0.51) | EGFRCCNT1CDK9MKNK1CDK2 | |
| SCHEMBL30883829 | 0.76 | EGFR (0.44) | MKNK2EGFRCCNT1CDK9MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-13 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| EP-3345906-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Wuxi Shuangliang Biotechnology Co., Ltd. (CN) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017035753-A1 | 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | 无锡双良生物科技有限公司 | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208585-A1 | 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF | ERBB2, EGFR, ERBB3 | MKNK2 1885/4885EGFR 2/4885CCNT1 2956/4885 |
| US-10377747-B2 | 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof | ERBB2, EGFR, ERBB3 | MKNK2 1906/4885EGFR 2/4885CCNT1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.